Abstract | Cyclic nucleotide phosphodiesterases (PDEs) catalyse the hydrolysis of cyclic AMP and cyclic GMP, thereby regulating the intracellular concentrations of these cyclic nucleotides, their signalling pathways and, consequently, myriad biological responses in health and disease. Currently, a small number of PDE inhibitors are used clinically for treating the pathophysiological dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease. However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.
Efficient integration of myriad extracellular and intracellular signals is required to maintain adaptive cellular functioning. Dysregulation of this integration promotes maladaptive cellular functions and underpins human diseases. Numerous distinct cellular signal transduction systems have evolved to allow cells to receive these various inputs, to translate their codes and, subsequently, to transduce and integrate their meanings. Two of these, the cAMP and the cGMP signalling systems (sometimes together referred to as the cyclic nucleotide signalling system), are among the earliest identified signal transduction systems. Advances in our understanding of the mechanisms by which cellular functions are altered through cyclic nucleotide signalling are enabling the identification and development of therapeutic agents for use in numerous human diseases.
The cAMP-and cGMP-signalling systems regulate a vast number of physiological processes, including visual transduction, cell proliferation and differentiation, gene expression, inflammation, apoptosis and metabolic pathways such as steroidogenesis, insulin secretion and glycogen synthesis, as well as glycogenolysis, lipogenesis and lipolysis [1] [2] [3] . Once synthesized by adenylyl cyclases or guanylyl cyclases, respectively, cAMP and cGMP transduce signal-encoded information by acting through a number of cellular effectors. These include cAMP-or cGMPactivated protein kinases (protein kinase A (PKA) or PKG, respectively), cyclic nucleotide-gated ion channels, a family of two cAMP-activated guanine nucleotide exchange proteins (exchange factors directly activated by cAMP 1 (EPAC1) and EPAC2) and a limited group of enzymes from the cyclic nucleotide phospho diesterase (PDE) family, which contain allosteric cyclic nucleotidebinding sites in addition to their catalytic sites [1] [2] [3] . Because the activities of several of these effectors can be altered simultaneously in response to increases in cellular cAMP or cGMP, cyclic nucleotide-elevating agents can trigger multiple cellular signalling events that -when integrated -yield a series of finely-tuned 'read-outs' and that markedly affect the numerous cellular functions listed above.
The functional impact and therapeutic utility of agents that increase the synthesis of either cAMP or cGMP have been established [4] [5] [6] [7] . Indeed, agents that are designed to act by binding to and activating selected G protein-coupled receptors (GPCRs), including drugs such as salmeterol (for asthma) 7 or exendin-4 (for diabetes) 8 , affect cellular functions by stimulating adenylyl cyclases. Similarly, agents that promote guanylyl cyclase-catalysed synthesis of cGMP have therapeutic utility; these include nitric oxide donor drugs such as glyceryl trinitrate (for angina therapy) 9 or the natriuretic peptide-inspired drugs 10 such as nesiritide, a recombinant form of human B-type natriuretic peptide (BNP). The functional impact and therapeutic utility of blocking cyclic nucleotide hydrolysis catalysed by cyclic nucleotide PDEs have also long been recognized. Indeed, Cyclic nucleotide phosphodiesterase (PDE) . A large gene superfamily of isozymes that catalyse the hydrolysis of the important intracellular messengers cAMP and cGMP.
Signalosomes
Localized macromolecular complexes, formed via protein-protein interactions, that contain cyclic nucleotide effectors and regulate the subcellular compartmentali zation of specific cyclic nucleotide signalling pathways. The incorporation of specific phosphodiesterases (PDEs) into signalosomes has established the crucial roles of individual PDEs in regulating specific cyclic nucleotide signalling pathways. This knowledge has spurred the development of more sophisticated strategies to target individual PDE variants and their interacting partners.
shortly after discovering that cAMP was the heat-stable factor responsible for the activation of hepatic glycogen phosphorylase by adrenaline, Sutherland and colleagues 11 identified the enzymatic activity of PDE as the cellular activity responsible for the hydrolysis of the 3′,5′ phosphodiester bond of cAMP to yield 5ʹ-AMP, and they identified caffeine as an inhibitor of this activity. Furthermore, caffeine, along with theophylline, was shown to potentiate the cAMP-increasing effects of adrenaline as well as the ability of adrenaline to activate phosphorylase or stimulate inotropic responses in perfused hearts 12 . These early findings highlighted the importance of PDEs as essential regulators of intracellular cyclic nucleotide concentrations and their biological effects. The subsequent years have seen the confirmation of the crucial roles of PDEs as regulators of intracellular cyclic nucleotide concentrations, as well as the discovery of a host of biological processes involving these second messengers in health and disease [1] [2] [3] . For these reasons, and others detailed in this Review, PDEs have consistently been considered to be key therapeutic targets, from both clinical and economic perspectives.
Nevertheless, at present only a few PDE inhibitors are in widespread clinical use. However, recent advances have renewed enthusiasm for further investigating their therapeutic potential. First, individual PDEs have been shown to control select cyclic nucleotide-regulated events by their integration into specific multi-molecular regulatory signalling complexes, termed 'signalosomes' , and through their regulation of cAMP or cGMP levels within distinct and largely non-overlapping intracellular cyclic nucleotide compartments 13, 14 . Indeed, there is evidence to suggest that the disruption of these signalling modules and the resultant dysregulation of this compartment-specific signalling via genetic, epigenetic or cellular environmental influences may be associated with many disease states, including asthma, inflammation, erectile dysfunction, hypertension, heart failure and cardiac arrhythmias 1-3, 13, 14 . Furthermore, it has been suggested that targeting these compartments could yield greater therapeutic specificity. There is growing confidence that this will be possible, given the recent remarkable advances in PDE biology and structural biology, including structure-function studies, advanced proteomics, X-ray crystallographic analysis of PDEs 15 and PDE-inhibitor complexes 16, 17 , as well as the development of more sophisticated strategies to examine the unique allosteric interactions between the catalytic and regulatory domains of PDEs 18 and to target specific PDEs in complex with their signalosome partners 19 . These advances may enable the development of effective therapies for a broad range of clinical applications, including asthma, inflammation, depression, stroke, schizophrenia, chronic cardiac failure and atherosclerosis. This Review focuses on these recent advances, as well as on translational research in the PDE field.
History of PDEs as therapeutic targets
Xanthine derivatives, including theophylline and caffeine, were clinically used as bronchodilators (for the treatment of asthma), diuretics and inotropic agents before they were identified as non-selective PDE inhibitors 20, 21 .
However, their unfavourable risk-benefit ratio and side-effect profiles considerably impeded their therapeutic success. In the 1970s and 1980s, simple gel filtration and ion exchange chromatography of tissue extracts revealed multiple peaks of PDE activities, with each peak exhibiting different specificities and affinities for cGMP and/or cAMP as well as different sensitivities to available pharmacological agents and effectors such as calcium/ calmodulin (the calcium/calmodulin-sensitive PDE is now known as PDE1) [22] [23] [24] [25] [26] . Consequently, drugs were successfully utilized to subdivide cAMP-hydrolysing PDEs into cilostamide-sensitive (now known as PDE3) and Ro20-1724-sensitive (now known as PDE4) enzymes 27 . Responsiveness to cGMP was also used to identify distinct PDEs: that is, cGMP-inhibited cAMP-hydrolysing PDEs (now known as PDE3) 25 , cGMP-stimulated cAMP-hydrolysing PDEs (now known as PDE2) 27 and cGMP-specific PDEs (now known as PDE5) 26 . Thus, molecular diversity among PDEs was recognized long before modern molecular biology and molecular genetics revealed the large number and complexity of PDEs, and before the current organization of the large mammalian PDE superfamily into 11 structurally related but functionally distinct PDE gene families (PDE1 to PDE11) [1] [2] [3] (FIG. 1) . The recognition that the molecular diversity of PDEs is coupled to the regulation of specific and functionally important physiological and pathophysiological processes (TABLES 1,2) has spurred the pharmaceutical industry to develop specific secondgeneration inhibitors that are selective for 9 of the 11 PDE families (TABLE 2) .
In the 1980s, PDE3 and PDE4 were the primary therapeutic targets. As PDE3 inhibitors were discovered to exhibit cardiotonic, inotropic, bronchodilatory and vasodilatory activities in several species, they were developed as cardiotonic agents to replace or add to cardiac glycosides in the treatment of cardiac failure 20, 28 . PDE4 inhibitors have antidepressive and anti-inflammatory activities, but were initially developed to treat chronic obstructive pulmonary disease (COPD) and asthma 20, 29, 30 . Unfortunately, the hopes that arose from preclinical studies were not completely realized in clinical trials, and many of these early second-generation PDE3 and PDE4 inhibitors were not approved owing to lack of efficacy and the presence of intolerable side effects 20, 28, 31 . As discussed below and listed in TABLE 2, other second-generation inhibitors of PDE3 and PDE4, with more favourable risk-benefit profiles, are now available 20, [30] [31] [32] and hold promise for use in additional disease states. During early unsuccessful clinical trials assessing the potential of the PDE5 inhibitor sildenafil (Viagra; Pfizer) in the treatment of angina and coronary artery disease, responses in off-target tissues dramatically changed the focus of this agent to erectile dysfunction. The enormous success of PDE5 inhibitors in treating erectile dysfunction 33 and, more recently, pulmonary hypertension 34 has been a major contributing factor in maintaining and expanding pharmaceutical interest in PDEs as promising therapeutic targets for many diseases (TABLE 2) . Overview of the PDEs Structural organization. The 11 structurally related but functionally distinct gene families (PDE1 to PDE11) that comprise the PDE superfamily differ in their cellular functions, primary structures, affinities for cAMP and cGMP, catalytic properties and responses to specific activators, inhibitors and effectors, as well as in their mechanisms of regulation 1-3 (FIG. 1; TABLES 1,2). Most families contain several PDE genes (for example, PDE1A, PDE1B and PDE1C (FIG. 1; TABLE 1) ), which together generate close to 100 PDE isozymes by alternative mRNA splicing or transcriptional processing.
As modular proteins, PDEs exhibit a common structural organization, with divergent amino-terminal regulatory regions (FIG. 1) and a conserved carboxy-terminal catalytic core. Some PDEs specifically hydrolyse cAMP (PDE4, PDE7 and PDE8), whereas others specifically hydrolyse cGMP (PDE5, PDE6 and PDE9), and some hydrolyse both (PDE1, PDE2, PDE3, PDE10 and PDE11) [1] [2] [3] . The N-terminal regulatory regions of PDEs contain structural determinants that target individual PDEs to different subcellular locations and signalosomes 13, 14, 19 , and also allow individual PDEs to specifically respond to different posttranslational modifications, regulatory molecules and signals. These structural elements include dimerization domains, autoinhibitory modules, binding sites for ligands and allosteric effectors, phosphorylation sites and other covalent modification sites, domains for isoform-specific protein-protein interactions with specific scaffolds and regulatory partners, and so on (FIG. 1) .
Most cells contain representatives of more than one PDE family, but in varying amounts, proportions and subcellular locations. Although PDEs exhibit a broad tissue distribution (TABLE 1) , some cells are relatively enriched in specific PDEs; for example, the photoreceptor PDE6 is almost exclusively expressed in retinal rods and cones
.
Architecture of the catalytic core of PDEs: implications for the design of inhibitors. X-ray crystal structures of isolated catalytic domains of nine PDE families (PDE1-PDE5 and PDE7-PDE10) 15 , of the near-full-length PDE2A 18 and of PDE4 catalytic domains with a fragment of upstream conserved regions (UCRs) 35 have demonstrated that the catalytic domains of PDEs share a similar topography, composed of ~350 amino acids folded into 16 helices. Across the PDE families, the active site forms a deep hydrophobic pocket that contains a PDEspecific, histidine-containing signature motif, HD(X 2 ) H(X 4 )N, and binding sites for two divalent metal ions that are essential for catalytic function 36 . Of the six invariant residues in the metal binding site, one (His160 in 1-3 contain amino-terminal subdomains (such as GAF domains, transmembrane domains, targeting domains, upstream conserved regions (UCRs), PAS domains and REC domains) and N-terminal hydrophobic regions that are important in subcellular localization, in the incorporation of PDEs into compartmentalized signalosomes, in interactions with signalling molecules and molecular scaffolds, and in the regulation of PDE activity. GAF domains regulate the allosteric binding of cGMP (to PDE2, PDE5, PDE6 and PDE11), the allosteric binding of cAMP (to PDE10) and the regulation of catalytic activity (in PDE2, PDE5 and PDE6). Phosphorylation sites are labelled on the figure. CaMKII, calcium/calmodulin-dependent protein kinase II; ERK2, extracellular signal-regulated kinase 2; PKA, protein kinase A; Pat7, 7-residue nuclear localization signal. PDE4D2) has been proposed to serve as a general acid for catalysis 15, 37 . The catalytic pocket is lined with highly conserved and invariant residues, including an invariant glutamine (Gln369 in PDE4D2, Gln453 in PDE9A2 and Gln726 in PDE10A2) that forms crucial hydrogen bonds with substrates (FIG. 2a,b ) and inhibitors 15, 16, 38, 39 (FIG. 2c,d) (see also Supplementary information S1 (figure), part A; Supplementary information S2 (figure)).
Analyses of crystal structures of PDE-inhibitor complexes (FIG. 2c,d ) (see also Supplementary information S1 (figure), part A; Supplementary information S2 (figure)) suggest that two conserved residues, the invariant glutamine and a highly conserved phenylalanine (Phe372 in PDE4D2; Trp621 in PDE11A2), are essential for inhibitor binding 15, 16, 36, 40 . The formation of hydrogen bonds with the invariant glutamine determines the orientation of inhibitors, and conserved hydrophobic residues (Ile336 and Phe340 in PDE4D2) 16, 40 form a 'hydrophobic clamp' that anchors inhibitors in the pocket and wedges their ring structures against Phe372 in PDE4D2 (Supplementary information S1 (figure), part A) 16, 36, 38, 40 and against Phe456 and Phe729 in PDE9A and PDE10A, respectively (Supplementary information S2 (figure)) 16, 17, [41] [42] [43] [44] [45] . • Endothelium permeability 193, 194 • Platelet aggregation 195 • NMDA receptor-induced LTP 196 • β 3 -adrenergic receptor-, nitric oxide-dependent cardiac contractility 59 • Natriuresis
192
• Atherosclerosis, inflammation, sepsis 193, 194 • Thrombosis
195
• Cognition and learning 196 • Heart failure 
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• Cardiac and vascular myocyte contractility and proliferation 28, 98, 121, 197, 198 • Platelet aggregation 100, 199 • Oocyte maturation 66, 67 • Adipogenesis, insulin and leptin-regulated intermediate metabolism 176, 200 • Heart failure, hypertension 28, 98, 121, 198 • Thrombosis
199
• Fertility 66, 67 • Obesity and satiety 176, 200 Enoximone 10 × 10 • CNS effects affecting cognition and mood 92, 93, 201 • Airway myocyte relaxation 202, 203 • Apoptotic cell death in malignant cells (DC-TA-46) 204 • Inflammation 29, 142 • Depression, anxiety, cognition enhancement, Alzheimer's disease and Parkinson's disease 92, 93, 201, 207 • Pulmonary inflammation, asthma and COPD 202, 203, 205, 206 • IBD (tetomilast; Phase III) 208 • Spondylitis and psoriatic arthritis (apremilast) 209 • Inflammation (quinolyl axazole) 210 • Cancer In addition to conserved elements that are responsible for binding to cyclic nucleotides and inhibitors, the catalytic core contains variable determinants that regulate PDE family-specific substrate and inhibitor affinities and selectivities 3, 17, 46 (TABLE 2) . Inhibitor selectivity for individual PDE families is regulated by these variable active site residues, which define not only the chemical nature of the interactions but also the slightly different sizes of the subpockets 38, 45, 47 . For example, the formation of a hydrogen bond between inhibitors and the variable Tyr424 residue of PDE9A, which is replaced by phenylalanine in other PDE families (except for PDE8), substantially improved the affinity and selectivity of PDE9 inhibitors 43, 44 (Supplementary information S2 (figure), parts A and B). In addition, most PDE families -that is, PDE1 to PDE4 and PDE7 to PDE10 -have relatively rigid pockets at the active sites, further constraining inhibitor structure with implications regarding binding specificity and family selectivity. This rigidity was demonstrated by the co-crystallization of two enantiomers of Merck's inhibitors L-869298 and L-869299 with PDE4D (Supplementary information S1 (figure), part B) 48 . L-869299 inhibits PDE4D 107-fold more weakly than L-869298 (with a half-maximal inhibitory concentration (IC 50 ) of 43 nM versus 0.4 nM). As both enantiomers assumed similar conformations or orientations owing to the rigidity of the PDE4D catalytic pocket, this suggested that L-869299 was forced to bind in an unfavourable orientation (Supplementary information S1 (figure), part B).
The catalytic domain of PDE5, however, appears to be unique for its ability to adopt multiple conformations of its helical H-loop (residues 660-683) and M-loop (residues 788-811) at the active site, upon binding to different inhibitors, including isobutyl-1-methylxanthine (IBMX), sildenafil and vardenafil (Levitra; Bayer) (Supplementary information S1 (figure), parts C and D). Crystal structures showed that both the H-and M-loops of PDE5 exhibit different conformations when sildenafil and vardenafil bind, which may account for the 5-20-fold differences in their IC 50 values and is probably related to their somewhat distinct core structures (Supplementary information S1 (figure), part D) 49, 50 . Although many of the family-selective inhibitors listed in TABLE 2 have been developed using classical medicinal chemistry approaches, a structure-based design approach is now the preferred path for generating novel inhibitors • PDE11 gene defects and mutations contribute to testicular and adrenal tumours, Cushing disease and psychiatric diseases 231 • Fertility
230
• Reduction of endocrine neoplasia 80,81
• Depression
231
ACTH, adrenocorticotropic hormone; CLL, chronic lymphocytic leukaemia, COPD, chronic obstructive pulmonary disease; CNS, central nervous system; GSK, GlaxoSmithKline; IBD, inflammatory bowel disease; LTP, long-term potentiation; NMDA, N-methyl-d-aspartate; PAH, pulmonary arterial hypertension; PDE, phosphodiesterase. *The original developers of the inhibitors are indicated in parentheses; otherwise, they are commercially available. ‡ Structural information was used in the discovery of these inhibitors. PDE inhibitors are also potential therapeutics for a broad range of diseases, with greater specificity and fewer side effects than the non-selective first-generation PDE inhibitors such as theophylline, caffeine and other xanthine derivatives (FIG. 1; TABLE 2 ).
Compartmentalization and the signalosome concept.
Early studies, particularly those reporting data that were consistent with the novel idea that cellular cAMP signalling was compartmentalized 51, 52 , were met with considerable resistance. Indeed, it was not until the purification of A-kinase anchor proteins (AKAPs) and their identification as selective subcellular PKA tethers 53, 54 that a potential mechanism for compartmentalized cAMP signalling was conceived. More recently, the use of several distinct types of cAMP biosensors, including those that utilize fluorescence resonance energy transfer (FRET), in combination with biochemical approaches, has confirmed that cells regulate their intracellular levels of cAMP or cGMP in a highly compartmentalized manner and generate functionally separate intracellular cyclic nucleotide pools [55] [56] [57] [58] [59] [60] . Briefly, compartmentalized cyclic nucleotide signalling is established via the formation of cyclic nucleotide signalosomes, in which unique combinations of cyclic nucleotide effectors (PKAs, EPACs, cyclic nucleotidegated ion channels or PKGs) and individual -or subsets of -PDEs form specific complexes via protein-protein interactions with one another and/or with localized scaffolding proteins, such as AKAPs, β-arrestin or receptor of activated protein kinase C1 (RACK1) 13, 14, 61 . Different AKAPs, for example, serve dual functions as tethers for PKA at different subcellular locations in close proximity to PKA substrates in order to promote selective phosphorylation, and as scaffolds for signalosomes with different proportions of PKA, adenylyl cyclases, other kinases, phosphatases, EPACs, PDEs and other effector molecules 13, 14, 61 . Thus, as components of specific signalosomes, PDEs modulate the diffusion and turnover of cyclic nucleotide gradients within spatially restricted and temporally regulated compartments, and they reduce the diffusion of cyclic nucleotide signals into neighbouring compartments. TABLE 3 and Supplementary information S3 (table) provide a comprehensive list of specific PDE-containing signalosomes, and include the specific PDE isoform and its signalling or interacting partners (both inferred and identified), the subcellular compartment or 'address' of the signalosome and the signalling pathway or cellular function regulated by the specific signalosome.
The integration of individual PDEs into specific signalosomes within different functional compartments has dramatically delineated the functional roles of individual PDEs and clearly linked the large number of PDE isoforms to the compartmentalized regulation of specific cyclic nucleotide signalling pathways and biological responses (TABLES 1,3). For example, PDE4B, PDE4D and PDE3A -as components of different, specifically localized, AKAP-based signalosomes in rodent cardiomyocytes -may regulate cAMP signalling within distinct cellular domains that regulate largely non-overlapping functions related to myocardial contractility
3). From a teleological perspective, the large number of known PDE isoforms readily meets the demands of the compartmentalized regulation of individual cyclic nucleotide signalling pathways, with its inherent requirement to tether or target different PDEs to specific signalosomes at many different intracellular locations [55] [56] [57] [58] [59] [60] . The incorporation of different types of PDEs into specific signalosomes (that is, PDEs from different PDE families and subfamilies or from different splice, transcriptional or translational variants, and so on), with their distinct intrinsic characteristics and regulatory properties, contributes to both the fine-tuning and specificity of compartmentalized cyclic nucleotide signalling 1-3,13,14 . In addition, different PDE isoforms can integrate multiple distinct cellular inputs and allow crosstalk between cyclic nucleotides and other signalling networks and systems 13, 14, 58, 59, [61] [62] [63] [64] . Although this substantial expansion in knowledge has revealed many new therapeutic opportunities, it has also raised additional questions and challenges regarding the development of specific therapeutics and the design of novel targeting strategies. Advances in the identification of protein components of signalosomes, in the biochemical understanding of protein-protein interactions and in the structural insights provided by X-ray crystallographic analyses of PDE catalytic cores and PDEinhibitor co-crystal complexes, as well as more complex structures, are allowing optimization of the structurebased design of competitive inhibitors that are selective for particular PDE families and subfamilies (BOX 1; TABLE 2). These advances are also beginning to permit the targeting of intramolecular interactions between the regulatory and catalytic regions of PDE molecules 18, 35 , as well as the targeting of intermolecular protein-protein interactions between PDEs and their regulatory partners 13, 14, 19, 58, 59, [61] [62] [63] [64] [65] . There is hope and confidence that this emerging confluence between PDE biology and structure-based drug design, together with the development of more sophisticated strategies to target specific PDEs in complex with their signalosome partners, will hasten the development of third-generation allosteric modulators and signalosome disruptors targeting individual PDEs that could be used to treat a broad range of diseases.
Biological and pathological roles of PDEs
Family-selective PDE inhibitors have been valuable in delineating the specific signalling pathways and cellular functions that are regulated by specific PDEs in animals and isolated cells 1-3 (TABLE 2) . However, the inability of most available agents to distinguish between the large numbers of family-specific isoforms expressed in most cells limits their value as probes to some extent. More compelling are studies of PDE-knockout mice, studies in which specific PDEs have been knocked down with small interfering RNA (siRNA) or studies highlighting the association of different PDE mutations with specific human diseases.
Indeed, data from these studies clearly demonstrate that the regulation of many cAMP-and cGMP-signalling pathways by specific PDEs is non-redundant, genetically determined and likely to be highly targetable (TABLES 1,2). For example, conclusive evidence that PDE3A is crucial for oocyte maturation was obtained when it was found that female Pde3a-knockout mice are sterile, most probably because PDE3A in oocytes regulates a specific cAMP pool that controls the activation of maturationpromoting factor (which is formed from the gene products of cyclin-dependent kinase 1 (CDK1) and cyclin B1 (CCNB1)) 66, 67 . Thus, Pde3a-knockout mice provide proof of principle that oocyte PDE3A could be a valuable contraceptive target; this hypothesis is supported by the fact that PDE3-selective inhibitors prevent pregnancy in rodents and block the maturation of cultured oocytes in many species, including rodents and humans 66, 67 . Results from similar experimental approaches have described numerous physiological and pathological roles of PDEs, as discussed below and in TABLES 1-3, and have thus encouraged the design and testing of new familyselective PDE inhibitors for use in numerous indications (TABLES 2,4).
Several human diseases are associated with mutations in genes encoding individual PDEs, or with mutations in genes encoding proteins that are involved in the expression or function of these PDEs (TABLE 1) 78, 79 . Inactivating PDE11A mutations were described in a subgroup of patients with
Box 1 | Structure-based design of PDE inhibitors
Many of the high-affinity, family-selective, competitive inhibitors listed in TABLE 2 were generated using classical medicinal chemistry approaches 16, 17 . This strategy, which almost exclusively identified compounds that competed with the binding of cyclic nucleotide substrates at the catalytic sites of phosphodiesterases (PDEs), involved screening extensive molecular libraries to identify lead compounds with modest potency and selectivity. These lead compounds served as scaffolds for systematic derivatization and chemical modification or optimization to produce second-generation, family-selective, competitive inhibitors with desired affinities, selectivities, potencies and favourable pharmacokinetics and safety profiles.
More recently, however, information from crystal structures of the catalytic sites of PDEs and of PDE-inhibitor complexes is driving the design of new inhibitors 15, 16, 17, 40, 163 . Lead candidates (usually of low affinity) are identified by a combination of compound library screening and high-throughput co-crystallization of PDE-inhibitor complexes. More potent and selective inhibitors are then generated by an iterative process of co-crystallography, whereby compounds are identified by additional focused library screening and/or they are chemically synthesized after structure-informed virtual screening and computational design. This approach has resulted in the discovery of several novel pyrazole derivatives as potent and selective PDE4 inhibitors 40, 163 , of pyrazolopyrimidinones (such as PF-04447943) as PDE9A inhibitors for cognitive disorders 43, 44 , and of pyridopyrazoloquinolines (such as PF-2545920) as PDE10A inhibitors for the treatment of schizophrenia 41, 42, 45 . In the latter case, the co-crystallization of lead scaffold triarylimidazole compounds (identified by high-throughput screening of the Pfizer compound library) with the catalytic fragment of PDE10A identified a unique, PDE10A-specific, hydrophobic selectivity pocket for PDE10A inhibitors. This structural information was crucial in the design and chemical synthesis of PF-2545920, a potent (with a half-maximal inhibitory concentration (IC 50 ) of 0.37 nM) and highly selective PDE10A inhibitor 45 . Cushing syndrome and bilateral micronodular adrenal hyperplasia 80 . Also, certain PDE11 mutations may increase susceptibility to prostate cancer 81 or to adrenal and testicular tumours in patients with Carney complex 82 , a disease that may be associated with inactivating mutations in the cAMP-dependent protein kinase type 1 alpha regulatory subunit (PRKAR1A) gene.
Alterations in cyclic nucleotide signalling pathways also affect neoplastic cellular transformation, tumour cell growth, progression and metastasis, as well as tumour cell function 83, 84 . Numerous PDE1-to PDE5-selective inhibitors, as well as PDE7-selective inhibitors, have been reported to inhibit growth and induce apoptosis in many different human cancer cell lines, which suggests a potential role for these drugs as antineoplastic agents (TABLES 1,2). For example, elevated PDE7B expression is associated with poor prognosis in chronic lymphocytic leukaemia (CLL), and selective PDE7 inhibitors (BRL-50481 and IR-202) increase cAMP-PKA signalling and apoptosis in CLL cells 85 . These data identify PDE7B as both a biomarker and a target for treating CLL. Similarly, inhibition of PDE4 activity or knockdown of PDE4D expression in malignant cells with elevated PDE4 activities caused growth inhibition and apoptotic cell death in the malignant cells, but not in the non-malignant cells 86, 87 . Re-expression of PDE4D inhibited cell death, which suggests that PDE4D might be both a tumour promoter and a therapeutic target in certain cancers. These beneficial effects of reducing PDE-mediated cAMP hydrolysis should, however, be tempered, given that cAMP can promote the growth of certain carcinomas and that apparently inactivating mutations in some PDEs (for example, PDE8 and PDE11) can predispose to endocrine tumours 88, 89 . The effects of PDE inhibitors on the permeability of the blood-brain barrier may also alter the effects of other therapeutic agents 90 . cAMP and cGMP signalling pathways are important in cognition as well as in behavioural function and dysfunction (TABLES 1,2) . Results of recent studies confirm that certain PDEs may be targets for ameliorating cognitive or behavioural deficits. Indeed, the PDE4 inhibitor rolipram, which was initially developed as an antidepressant 91 , improves cognition and long-term memory in rodents 35, 92, 93 . At a molecular level, the observation that Pde4d-knockout mice exhibit antidepressive behaviour and show reduced antidepressant responses to rolipram but not to other antidepressant drugs supports a role for PDE4D in cognition, memory and antidepressive behaviour, whereas Pde4b-null preclinical models implicate this enzyme in anxiety-related behaviour 35 in DISC1 (disrupted in schizophrenia homolog 1) and polymorphisms in PDE4B are both associated with schizophrenia 75 , and DISC1 and PDE4B interact physically in cells to influence the catalytic activity of PDE4B 94, 95 ; together, these observations support the notion that PDE4B is involved in schizophrenia. In preclinical rodent models, highly selective PDE10A inhibitors elicited antipsychotic and pro-cognitive responses, and also increased sociality 41, 42, 93 (TABLE 2) . Also, inhibition of PDE4 or PDE10A alleviated motor and behavioural deficits in a transgenic R6/2 mouse model of Huntington's disease, in which alterations in striatal PDE10A preceded the motor symptoms of the disease 96, 97 . These studies have increased interest in developing PDE inhibitors as therapeutics for basal ganglia disorders.
PDE inhibitors in the clinic
Although many high-affinity, PDE-family-selective, competitive inhibitors have been generated, only a limited number of second-generation agents have received regulatory approval for widespread clinical use. Below, we describe some of the agents that are in widespread use and those that may soon gain regulatory approval. A more comprehensive list of the agents that are currently under development and in clinical trials is provided in 98, 99 . Milrinone is approved, however, for the acute treatment of adults with decompensated and refractory heart failure, and those awaiting heart transplants 98 . Another PDE3 inhibitor, cilostazol (Pletal; Otsuka Pharmaceutical), is approved and widely used to treat intermittent claudication, a relatively common lower-extremity peripheral arterial disease that is characterized by ischaemia-induced leg pain or cramping 100, 101 . Cilostazol increases walking distance and reduces the clinical symptoms of intermittent claudication by cAMP-mediated vasodilation and the inhibition of platelet activation and vascular wall inflammation 100, 101 . PDE4 inhibitors. PDE4 isoforms have a relatively high level of expression in cells that regulate immunoinflammatory responses and tissue remodelling 29 . Because early PDE4-selective inhibitors -especially rolipram -exhibited potent cAMP-mediated anti-inflammatory responses in various cellular and animal models, pharmaceutical companies invested heavily in developing PDE4 inhibitors for clinically important, inflammation-related pulmonary diseases, including COPD, asthma, allergic rhinitis and idiopathic pulmonary fibrosis [29] [30] [31] . COPD is a major public health concern and a leading cause of death in societies where smoking is prevalent. Clinically, COPD is characterized by progressive airway inflammation and obstruction, as well as a decline in lung function, with acute Box 2 | Signalosome coupling of cAMP-PKA signalling to myocardial contractility
In the rodent heart, activation of β-adrenergic receptors increases myocardial contractility by coupling cAMP-protein kinase A (PKA) signalling to intracellular calcium cycling 166 . PKA-induced phosphorylation of L-type calcium channels in T-tubules and of ryanodine-sensitive calcium channels (also known as ryanodine receptor 2 (RYR2)) in the sarcoplasmic reticulum (SR) increase calcium influx and calcium-induced calcium release from the SR during systole, respectively. Phosphorylation of phospholamban (PLB) blocks its inhibitory interactions with sarcoplasmic/ endoplasmic reticulum calcium ATPase 2 (SERCA2), the calcium-transporting ATPase of the SR, and results in increased calcium accumulation in the SR during diastole 166 (FIG. 3) . These actions increase the amplitude of myocardial calcium transients, resulting in enhanced inotropic and lusitropic responses.
As components of different A-kinase anchor protein (AKAP)-based signalosomes, phosphodiesterase 4B (PDE4B), PDE4D and PDE3A each regulate different phases of the calcium-mediated excitation-contraction coupling cycle 166 . AKAP15/AKAP18 is important in the targeting and tethering of PKA and PDE4B to L-type calcium channels; AKAP6 (also known as mAKAP) in the targeting and tethering of PDE4D to RYR2; and AKAP18δ in the targeting and tethering of PDE3A to SERCA2-PLB regulatory complexes (known as signalosomes) [167] [168] [169] . In this manner, PDE4B regulates cAMP-PKA-stimulated calcium influx, PDE4D regulates calcium-induced calcium release from the SR, and PDE3A regulates increased accumulation of calcium in the SR [167] [168] [169] . A PDE4D variant has also been reported to associate with SERCA2 in the rodent heart 170 . Studies in Pde4b-and Pde4d-knockout mice strongly suggest that compartmentalized PDE4B and PDE4D are crucial for maintaining the physiological equilibrium between PKA-induced channel phosphorylation and excitationcontraction coupling, as hyperphosphorylation of L-type calcium channels and RYR2 channel proteins in Pde4b-and Pde4d-knockout mice (owing to increased cAMP-PKA signalling), respectively, leads to alterations in intracellular calcium cycling, ventricular arrhythmias and cardiac dysfunction [167] [168] [169] . In the rodent heart, a macromolecular complex containing the phosphoinositide 3-kinase γ-subunit (PI3Kγ), PDE3A, PDE4A and PDE4B was recently proposed to have a protective role against ventricular arrhythmias by regulating the phosphorylation of L-type calcium channels and PLB 171 . Although PDE4 protects against cAMP-PKA-induced arrhythmias in isolated human atrial myocytes 172 , the role of PDE4 isoforms in human cardiac function is uncertain, as there are potential cardiovascular risks that might accompany the chronic usage of drugs such as roflumilast (approved for the treatment of chronic obstructive pulmonary disease), which inhibit all PDE4 isoforms. A recent report has identified a crucial role for PDE3, but not PDE4, in regulating β 1 -and β 2 -adrenergic receptor-mediated effects on myocardial contractility in the hearts of patients with heart failure recurrences and exacerbations that lead to a markedly reduced quality of life and eventual death. Although the development of rolipram and other PDE4 inhibitors was hampered owing to their gastrointestinal side effects, especially nausea, emesis and diarrhoea, the potential of the target encouraged further industry investment and led to the development of more advanced PDE4 inhibitors. Two inhibitors, cilomilast and roflumilast, reached Phase III trials [29] [30] [31] ; roflumilast (Daliresp/Daxas; Takeda/ Nycomed) is now approved as an oral treatment for reducing the risk of exacerbations in patients with COPD who also have chronic bronchitis [29] [30] [31] [32] (TABLES 2,4).
PDE5 inhibitors.
Male erectile dysfunction is a widespread and distressing condition and is often associated with significant co-morbidities, including hypertension, hyperlipidaemia, atherosclerosis and diabetes 33 . As cGMP is a crucial physiological regulator of the nitric oxide-induced vasodilation (which leads to penile erection) that occurs upon sexual stimulation, and given that PDE5 has a relatively high expression in the corpus cavernosum, PDE5 inhibitors can be used to prevent the destruction of cGMP and thereby enhance erectile function in unaffected men or in patients with erectile dysfunction (secondary to deficiencies in nitric oxide-cGMP signalling) 33 . Orally administered PDE5 inhibitors, the first being sildenafil, followed by vardenafil and tadalafil (Cialis; Eli Lilly), have been highly successful in treating erectile dysfunction. Avanafil (Stendra; Vivus), a rapidly acting PDE5-selective inhibitor, has also been approved for the treatment of erectile dysfunction (TABLES 2,4).
Pulmonary arterial hypertension is characterized by increased mean pulmonary artery pressure and increased pulmonary vascular resistance resulting from vasoconstriction and hypertrophic structural remodelling of the small pulmonary arteries, which leads to decreased oxygenation of blood, dyspnoea, decreased exercise capacity, reduced quality of life, heart failure and, eventually, death 34, 102, 103 . PDE5, which has a relatively high expression in the airway and vascular smooth muscle, is thought to be a key regulator of pulmonary vascular dilation and remodelling via its modulation of cGMP-PKG signalling. PDE5 inhibitors such as sildenafil (marketed as Revatio by Pfizer), tadalafil (marketed as Adcirca by Eli Lilly) and vardenafil are currently approved for the treatment of pulmonary arterial hypertension 34, 102, 103 . Today, xanthine derivatives (for example, theophylline and caffeine), which inhibit almost all PDE families (except for PDE8 and PDE9), are clinically used primarily as bronchodilators in the treatment of pulmonary diseases such as asthma, chronic bronchitis, emphysema and COPD 20, 21 . Another xanthine derivative, pentoxifylline (Trental; Sanofi) is used to treat intermittent claudication secondary to chronic occlusive arterial disease. 167 . AKAP6 (also known as mAKAP) serves as a scaffold for a PDE4D3-containing signalosome that is involved in regulating the release of calcium from the sarcoplasmic reticulum via the ryanodine receptor channel 168 . PDE3A, as a component of a sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA)-AKAP18δ-containing signalosome, is an important regulator of the effects of cAMP on calcium uptake into the sarcoplasmic reticulum 169 . NCX, sodium/calcium exchanger; PKA, protein kinase A; PKA-C, PKA catalytic domain; PKA-R, PKA regulatory domain; PLB, phospholamban; PMCA, plasma membrane calcium-transporting ATPase; PP2A, protein phosphatase 2A; Rg, PP2A regulatory subunit; TNNC, troponin C; TNNI, troponin I. These drugs, however, exhibit a narrow therapeutic window, and toxicity (nausea, emesis and arrhythmias) is a major concern 20 . Theophylline is also currently being considered as an important add-on therapy in corticosteroid-resistant asthma and COPD 21 (ClinicalTrials.gov identifier: NTC00241631). Dipyridamole, another nonselective PDE inhibitor, inhibits platelet aggregation and is used to prevent post-surgical thromboembolic events and stroke 104 .
Limitations of existing agents. Despite the therapeutic success of several PDE3, PDE4 and PDE5 inhibitors, offtarget effects limit their use. Although these inhibitors predominantly inhibit specific PDE families and not virtually all PDEs, as is the case with methylxanthines, they unfortunately inhibit all family members, even those in off-target locations, which produces undesirable effects. The importance of understanding these off-target effects is increasingly being realized, as they can both positively and negatively influence the risk-benefit profile of PDE inhibitors. For example, in the case of the PDE3 inhibitor milrinone, it is not known whether its cardiotoxicity is related to its inhibition of both PDE3A and PDE3B, its inhibition of different pools of cardiac PDE3A that differentially regulate contractility and apoptosis, its inhibition of other PDE families or to its interactions with non-PDE proteins 98 . Similarly, the PDE4 inhibitors rolipram and cilomilast failed in clinical trials because of the dose-limiting nausea-and emesis-associated offtarget effects caused by the inhibition of PDE4 isoforms, possibly PDE4D, in the emetic centre in the brain 20, 31 . Conversely, some off-target effects of family-selective PDE inhibitors can positively affect their efficacy and/ or their safety profile. For example, it has been suggested that sildenafil-induced inhibition of PDE1 may be responsible for some of the beneficial effects of this PDE5 inhibitor in treating heart failure 98, 102 . Indeed, PDE1 is more highly expressed than PDE5 in the human myocardium, and inhibition of PDE1 in preclinical models of heart failure blocks pathological vascular remodelling and cardiac hypertrophy 105, 106 . Should the unexpected protective effects of sildenafil in the heart be related to PDE1 inhibition, these data would support the notion that dual PDE1 and PDE5 inhibition might be beneficial in treating human cardiovascular diseases. Similarly, the ability of cilostazol to block adenosine uptake into the myocardium (via mechanisms other than the inhibition of PDE3) may be related to the reduced cardiotoxicity observed during chronic administration of cilostazol as compared to that observed following the chronic administration of milrinone [99] [100] [101] 107 . The use of PDE family-selective inhibitors can also be limited by their direct or indirect inhibition of other PDE family enzymes and/or their interaction with non-PDE proteins to cause unacceptable toxicity, as well as by the roles of multiple PDE families in regulating signalling pathways. As for interacting with non-PDE proteins, the PDE5 inhibitor vardenafil has been reported to block calcium channels in rabbit pulmonary arteries and human platelets 108 , and sildenafil has been reported to interact with multidrug resistance protein 1 (MDR1; also known as ABCB1) and antigen peptide transporter 1 (APT1; also known as ABCB2) to block drug extrusion from cells 109 . This latter off-target effect could be potentially quite important in serving to reduce ABCB1-and ABCB2-mediated drug resistance and thus improve the efficacy of some chemotherapeutic agents, perhaps independently of PDE5 inhibition 109, 110 . Nonspecific PDE inhibitors may inhibit multiple PDEs and interact with many proteins, which may alter the efficacy of these compounds. For example, because the methylxanthine theophylline is a purine derivative, it inhibits almost all PDEs and also interacts with many other proteins, producing both beneficial and toxic effects 31, 111 . Although the bronchodilatory effects of theophylline are most probably related to PDE inhibition in the airway smooth muscle, its anti-inflammatory actions -which are mediated in part via inhibition of the nuclear translocation of nuclear factor-κB (NF-κB) -may be attributed to both PDE inhibition (similar to the effects of the PDE4 inhibitor NCS 613) 112 and to increased cAMP signalling 113, 114 , as well as to effects that are independent of this activity 111, 115 . Indeed, theophylline directly activates phosphoinositide 3-kinase δ-subunit (PI3Kδ), which, in turn, activates histone deacetyl ases (HDACs) and thus augments the anti-inflammatory effects of glucocorticoids 111, 115 . Theophylline also binds to adenosine receptors, and although blocking adenosine A 2B receptors may be beneficial in preventing adenosineinduced mediator release from mast cells, blocking adenosine A 1 receptors could account for serious untoward effects, including cardiac arrhythmias and seizures 31, 111 . Last, inhibition of PDE4 could account, in part, for theophylline-induced nausea and diarrhoea 31, 111 .
New uses, drugs and development approaches
The enormous clinical success of PDE5 inhibitors has spurred continued interest in PDE inhibitors as potential therapeutics as well as in approaches to overcome the limitations of current PDE inhibitors. In addition, the emerging concept that many individual PDEs or subsets of PDEs are selectively localized or recruited to specific cellular compartments where they are integrated into specific signalosomes provides insight into their specific functional roles in health and disease, as well as their potential as novel therapeutic targets.
The level of interest in PDE inhibitors can be readily appreciated from the large number of clinical trials registered on the ClinicalTrials.gov website; some of these trials are listed, along with their indications and associated NCT designations, in TABLE 4. Many of these trials are in Phase IV, involve US Food and Drug Administration (FDA)-approved PDE3, PDE4 and PDE5 inhibitors, and are designed to provide additional information about the efficacy of these inhibitors in subpopulations of currently targeted patients or in novel clinical applications (TABLES 2,4). In addition, a substantial number of trials (TABLE 4) are investigating novel PDE inhibitors in the treatment of diseases for which PDE inhibitors are already approved -that is, COPD, pulmonary hypertension and erectile dysfunction -or for additional diseases. Trials investigating the use of PDE1 inhibitors for the treatment of vascular remodelling or schizophrenia, PDE7 inhibitors for the treatment of inflammation or leukaemia, and PDE10A inhibitors for the treatment of neuropsychological disorders are all in progress. Because of the complexity of many diseases, such as COPD, asthma and type 2 diabetes, there is also increasing interest in utilizing multiple PDE inhibitors or developing inhibitors that target several particular PDEs to provide more effective therapies with more favourable risk-benefit profiles.
Novel applications of PDE inhibitors PDE3 inhibitors. A substantial number of trials are testing currently approved PDE inhibitors in other conditions (TABLE 4) . For example, clinical studies have suggested that the PDE3 inhibitor cilostazol, perhaps owing to its anti-inflammatory effects as well as its ability to inhibit platelet aggregation and vascular smooth muscle proliferation 100 , may attenuate post-angioplasty restenosis (the 'cilostazol for restenosis' (CREST) trial) [116] [117] [118] or reduce the progression of atherosclerosis in diabetes (the randomized 'diabetic atherosclerosis prevention by cilostazol' (DAPC) trial) 119, 120 . The vascular smooth muscle cell (VSMC)-proliferation-stimulating component of this potential activity is underpinned by data obtained using VSMCs derived from Pde3a-null mice 121 . Aortic VSMCs of Pde3a-deficient mice, but not those from Pde3b-null mice, exhibited dysregulated cAMP-PKA signalling and mitogen-activated protein kinase (MAPK) signalling as well as reduced mitogen-induced VMSC proliferation 121 . PDE1 may also be a crucial regulator of pathological vascular and airway smooth muscle remodelling 105 . In normal vessels, VSMCs exhibit a quiescent or contractile phenotype, which is geared to maintain vascular tone. In response to injury and/or endothelial dysfunction, VSMCs shift to a synthetic or proliferative phenotype in which the induction of PDE1C removes the inhibitory effects of cAMP on growth. siRNA-induced knockdown of PDE1A or pharmacological inhibition of PDE1A with IC83640 (a PDE1-selective inhibitor) blocked cell cycle progression in proliferating VSMCs 105 . Similarly, PDE1C knockdown in VSMCs derived from pulmonary hypertensive arteries increased cAMP and inhibited proliferation 105 . Thus, targeting PDE1C 105 and/or PDE3A 121 in vessels might, via increased cAMP signalling, block the growth of VSMCs and reduce the vascular remodelling that occurs in pulmonary hypertension, atherosclerosis, post-stenting restenosis and after angioplasty, as well as certain cardiomyopathies.
PDE4 inhibitors in inflammatory disorders.
Given their potent anti-inflammatory effects, PDE4 inhibitors might be useful for treating diseases involving aberrant immune responses, such as atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease and type 1 diabetes [29] [30] [31] 35, 122, 123 . As shown in TABLE 4, apremilast -a second-generation PDE4 inhibitor -is in Phase II and Phase III trials for use in psoriasis and psoriatic arthritis 31, 123 . Studies with Pde4a-, Pde4b-and Pde4d-null mice [124] [125] [126] demonstrated that only the Pde4b-null mice failed to develop airway inflammation (that is, T helper 2 (T H 2) cytokine production and eosinophil infiltration) or acute airway hyperactivity in response to antigen-induced challenge 92 . Other findings are consistent with the idea that inhibition of PDE4D in particular, rather than other PDE4 isoforms, is associated with the dose-limiting gastrointestinal side effects of PDE4 inhibitors, whereas PDE4B seems to have an important role in acute activation of the T cell receptor (TCR) [124] [125] [126] [127] . Studies such as these have provided the rationale for the development of PDE4B-selective inhibitors as potential therapeutics for allergic inflammation and asthma 92 , and the development of PDE4D-selective allosteric modulators (as discussed below) to reduce inflammation and improve cognition 35 . Recent studies exploring the biology of the nonspecific PDE inhibitor resveratrol 128, 129 may have important implications for future clinical applications of PDE4 inhibitors. In animal models, resveratrol -a poly phenol found in red wine -protects against diet-induced obesity, type 2 diabetes and some of the cardiovascular complications associated with these disorders 128 . Indeed, recent findings have suggested that many of the pleiotropic beneficial effects of resveratrol may be mediated via its nonspecific inhibition of PDEs, especially PDE4, as the metabolic benefits of resveratrol in mice 129 were mimicked by the inhibition of PDE4 with rolipram. Indeed, when compared to littermates that were fed a high-fat diet, Pde4b-knockout mice gained less weight and had less obesity-induced inflammation 130 . Perhaps more importantly, significant weight loss was reported in participants receiving roflumilast in clinical trials 30 . Roflumilast has also recently been reported to reduce levels of glycated haemoglobin and blood glucose in patients with newly diagnosed type 2 diabetes 131 .Thus, PDE inhibitors, especially PDE4 inhibitors, may be useful for treating certain metabolic diseases, including obesity, type 2 diabetes and metabolic syndrome 132 . Given the current understanding of the crucial role of inflammation in these diseases 133 , the anti-inflammatory actions of PDE4 inhibitors may provide considerable therapeutic benefit. (TABLE 4) are in progress investigating PDE5 inhibitors in heart failure as well as in Duchene and Becker muscular dystrophy (the 'Revatio for Heart Disease in Duchenne and Becker Muscular Dystrophy' REVERSE-DBMD trial). Indeed, there is considerable excitement regarding the potential use of PDE5 inhibitors as therapeutics for cardiovascular diseases 102 , including hypertension, ischaemic cardiomyopathy, cardiac failure, stroke, peripheral myopathy and cardiac dysfunction in Duchenne muscular dystrophy, as well as insulin resistance, type 2 diabetes and metabolic syndrome 33, 34, 98, 102, 103, 132, [134] [135] [136] .
PDE5 inhibitors. Clinical trials
In rodent heart models of ischaemia-reperfusion injury, sildenafil has a cardioprotective effect and limits infarct size, perhaps by increasing cGMP-PKG signalling, which results in the opening of mitochondrial ATP-sensitive potassium channels, thus limiting the accumulation of calcium in mitochondria and preventing cell death 102 . In the rodent heart, sildenafil blocked the development of cardiac hypertrophy induced by transaortic constriction or by the β-adrenergic receptor agonist isoprenaline. Remarkably, in the mdx mouse model of Duchenne muscular dystrophy, sildenafil prevented or reversed the cardiac dysfunction and cardiomyopathy characteristically observed in these mice. Similar to their effects on pulmonary circulation, PDE5 inhibitors may improve cerebral circulation and oxygenation and thus protect the brain against stroke 102 . PDE10 inhibitors and other PDE inhibitors in nervous system disorders. PDE10 inhibitors are being considered as cognition enhancers and as therapeutics for cognitive dysfunction, based on preclinical studies that have demonstrated the beneficial effects of these agents on learning and memory as well as on cognitive and behavioural defects in complex neuropsychological disorders such as schizophrenia. As of 2012, for example, ~25 PDE4 inhibitors and ~10 PDE10A inhibitors had been granted patents that claimed a positive effect on learning and memory 137 . Another report 138 indicated that more than 20 companies had published patent applications targeting PDE10A for central nervous system (CNS) research purposes, especially schizophrenia 41, 42, 93 . PDE10A inhibitors, which have been shown to have antipsychotic effects in rodent models 41, 42, 138 and to exhibit antipsychotic and pro-cognitive effects as well as enhance social behaviour in mice 139 , are in clinical trials for the treatment of schizophrenia (TABLE 4) . A PDE1 inhibitor, ITI-214, is in trials for the treatment of cognitive deficits associated with schizophrenia and other neuropsychiatric disorders 140 . Other companies are also developing PDE inhibitors to target these diseases (TABLE 4) . There is also interest in utilizing inhibitors of PDE10A and PDE4 in Huntington's disease 93, 141 (TABLE 4).
Combinatorial PDE inhibition
Although individual PDEs regulate selective cAMP signalling pathways, the dysregulation of multiple signalling pathways contributes to the pathogenesis and clinical presentations of complex diseases such as COPD and diabetes 142, 143 . It is therefore likely that several PDEs may need to be targeted for effective treatment. Targeting multiple PDEs (with multiple drugs or with individual drugs that have mixed selectivities) in several target cells could theoretically produce additive or synergistic effects and lead to more effective therapies, so that drugs could perhaps be administered at lower doses and induce fewer side effects (TABLES 2,4). Novel secondgeneration, non-selective PDE inhibitors (analogous to theophylline and resveratrol) might also provide simultaneous inhibition of multiple PDEs and the activation of several signalling pathways, thereby producing additive or synergistic beneficial effects in these and other complex diseases.
A major impetus to consider dual PDE inhibitor therapy relates to the desire to take full advantage of the powerful anti-inflammatory effects of PDE4 inhibitors, such as roflumilast, as the narrow window between their anti-inflammatory effects and their side effects (which include nausea and emesis) may limit their application in many inflammatory diseases. The anti-inflammatory effects of PDE4 inhibitors are not identical in all immuno inflammatory cells, and inhibitors of PDE7 and PDE3 can enhance the effects of PDE4 inhibitors in T cells and macrophages, respectively 31, 143, 144 . With respect to diseases such as asthma, PDE4 inhibitors are not broncho-or vasodilators. Thus, although new PDE4 inhibitors with reduced emetic effects are in development (for example, the PDE4D allosteric modulator D159687) 31, 35 , a combinatorial approach could maximize the efficacy of PDE4 inhibitors without adversely affecting their risk-benefit ratios 143, 145 . Dual PDE8-PDE4 inhibitors. Studies utilizing familyselective PDE8 inhibitors, as well as studies using Pde8a-knockout mice, Pde8b-knockout mice and Pde8a -/-Pde8b -/-double-knockout mice, demonstrated that PDE8A and PDE8B have both specific and overlapping roles in regulating the basal rates of steroid production in rodent Leydig and adrenal cells 76, 77 . PDE8 inhibitors, however, clearly synergized with PDE4 inhibitors in regulating the maximal rates of cAMP-stimulated steroidogenesis 77 . These studies clearly demonstrated that functionally interacting cAMP pools or compartments can be regulated by multiple PDEs.
Dual PDE1-PDE4 inhibitors.
There is evidence indicating that combined PDE1 and PDE4 inhibitors could have utility in pathological airway remodelling (mediated by PDE1) and pulmonary inflammation 105, 143 . Airway remodelling (thickening of the wall owing to hyperplasia or hypertrophy) and increased airway hyperreactivity are characteristic of the pro-inflammatory phenotypes of asthma and COPD. PDE1 inhibitors block smooth muscle mitogenesis and could complement the antiinflammatory effects of PDE4 inhibitors 105, 143 . KF19514, which inhibits both PDE1 and PDE4, was reported to reduce airway remodelling and inflammation in a murine model of asthma 143, 145 . Dual PDE4-PDE7 inhibitors. PDE7A is widely expressed in immunoinflammatory cells, especially T lymphocytes, but its functional role is not certain, and selective PDE7 inhibitors do not markedly alter normal T cell function 143, 144 . However, the co-expression of PDE4 and PDE7 in most immunoinflammatory cells and the synergistic effects of PDE7-and PDE4-selective drugs in the suppression of inflammation in cell-based studies have fuelled speculation that dual inhibition of PDE7 and PDE4 could be an effective strategy to treat asthma, COPD and other diseases characterized by a pro-inflammatory phenotype 143, 146 . Dual PDE3-PDE4 inhibitors. As PDE3 inhibitors 147 are bronchodilators and, similar to PDE7 inhibitors, they increase the effects of PDE4 inhibitors in immunoinflammatory cells (especially macrophages) 143, 148 , several pharmaceutical companies have developed inhibitors with dual selectivity for PDE3 and PDE4 as potential therapeutics for asthma and COPD 145, 148, 149 (TABLES 2,4). So far, no lead scaffolds generated through structure-based design have been reported. Some attempts have generated hybrid compounds with distinct PDE3 and PDE4 pharmaco phores separated by a linker 149 . Two early dual PDE3-PDE4 inhibitors (zardaverine and benafentrine) had modest and short-lived bronchodilatory effects in humans 150 . Another PDE3-PDE4 inhibitor, RPL554 (a pyrimidoisoquinolinone derivative with IC 50 values of 107 nM and 1.2 μM for PDE3 and PDE4, respectively), is in trials for COPD, allergic rhinitis and asthma 151 . Alternative approaches for targeting PDE4 in pulmonary disease include the development of inhaled PDE4 inhibitors or inhaled antisense oligonucleotides targeting specific PDE4 isoforms, as well as combinations of PDE4 inhibitors and inhaled corticosteroids or β-adrenergic receptor agonists. For example, the inhaled PDE4 inhibitor GSK256066 significantly reduced early and late responses to inhaled allergen in a small trial studying 24 patients with asthma 152 . In COPD, roflumilast can be used alone or together with standard bronchodilator treatments, such as salmeterol (a long-acting β 2 -adrenergic receptor agonist (LABA)) or tiotroprium (a short-acting anticholinergic drug) 30, 145 .
Novel signalosome disruptors
As discussed above, individual PDEs are recruited in an isoform-specific manner into specialized signalosomes within discrete functional compartments, where they can tightly regulate local cyclic nucleotide concentrations and gradients 13, 153 (TABLE 3) . As a corollary to the signalosome hypothesis, there are data supporting the therapeutically relevant proposition that the disruption of cyclic nucleotide-mediated events within specific individual signalosome-based compartments will have more specific effects than agents that do not discriminate between these compartments and instead inhibit other members of the same PDE family 9, [61] [62] [63] [64] [65] . It should be possible to target events that are coordinated by individual signalosomes. This could be achieved by disrupting the integration of individual proteins into these signalosomes during their formation or, more conceivably, by displacing individual proteins from pre-formed or dynamically forming signalosomes in cells using small-molecule antagonists 154, 155 or 'disruptor peptides' 156 to antagonize protein-protein interactions. Examples of small molecules or peptides include those designed to displace PKA regulatory subunits from AKAPs 154, 155 or other scaffolding proteins [156] [157] [158] [159] , peptides designed to antagonize the interaction of PDEs with cyclic nucleotide effectors 19, 57 , and peptides designed to disrupt PDE-EPAC interactions 57, 62, 63 (FIG. 4) .
Peptide-based therapeutic agents have some advantages over traditional small-molecule drugs, such as their high potency and selectivity, their low toxicity and biological accumulation in tissues as well as their high diversity. Conversely, their physicochemical properties make them unsuitable for simple oral delivery, and without modification they have relatively poor bioavailability and low metabolic stability. Indeed, small unconjugated linear peptides composed exclusively of natural amino acids are easily degraded by numerous peptidases and are efficiently removed from the circulation by the kidney. However, although these disadvantages have limited the use of peptide-based therapeutics, recent advances with the potential to dramatically enhance the membrane permeability and metabolic stability of these agents are increasingly enabling their clinical use 160 .
Disruptors of targeted PDEs PDE4. In human arterial endothelial cells (HAECs), the inhibitory effects of cAMP on cell permeability, mediated via the activation of EPAC1-RAP1 (small GTPase RAS-related protein 1) signalling, are regulated through a PDE4D-containing, EPAC1-based, cAMP signalosome 57, 62, 63 (FIG. 4) . The use of traditional PDE4 inhibitors (such as rolipram and Ro20-1724) or an EPAC1-based PDE4D-disrupting peptide led to the activation of RAP1 by EPAC1 within this complex and promoted HAEC barrier integrity (FIG. 4) . Further studies are needed to assess the impact of disrupting PDE4D-or EPAC1-mediated endothelial barriers in vivo under conditions of vascular inflammation. Similarly, in isolated cardiomyocytes, a peptide that selectively disrupted the association of PDE4D5 with heat shock protein 20 (HSP20) increased local cAMP-PKA-induced phosphorylation of HSP20 and reduced the catecholamine-induced hypertrophic response in this model system 19, 161 . Such an approach could have utility in limiting cardiac hypertrophy, and studies to test this hypothesis are underway.
Although these studies highlight the functional consequences of disrupting these complexes in cells, further studies will be required to assess their functional selectivity in more physiological settings. Indeed, in the context of displacing PDE4D5 in cardiomyocytes, this approach might be limited by potentially arrhythmogenic effects resulting from cAMP-PKA-induced hyperphosphorylation of the L-type calcium channel (BOX 2). In this context, studies with Pde4b-knockout mice highlight the potential benefits of targeting PDE4B-containing signalosomes in immunoinflammatory cells in conditions including COPD and asthma 92, 162 , as opposed to the potentially arrhythmogenic effects of targeting PDE4B-containing signalosomes in cardiomyocytes (BOX 2) . Finally, in a breast cancer cell model system, a peptide that selectively blocked the interaction between PDE4D5 and the scaffold protein RACK1 -in a complex composed of focal adhesion kinase (FAK), RACK1 and PDE4D5 -inhibited the invasion potential of the cultured cancer cells and might provide a novel avenue for limiting the invasion of certain cancer cells 157 .
PDE3.
In the same HAEC cultures in which barrier function was shown to be locally regulated by a PDE4D-and EPAC1-based signalosome, a PDE3B-containing, EPAC1-based cAMP signalosome was also shown to selectively coordinate the effects of cAMP on HAEC adhesion, migration and tubule formation via the control of RAS-related protein (RRAS) and PI3Kγ signalling 57 (FIG. 4) . As with the PDE4D-EPAC1 complex that regulated HAEC permeability, the addition of either a PDE3 inhibitor (cilostamide) or of a PDE3B-based EPAC1-disruptor peptide promoted cAMP-mediated activation of RRAS and the RRAS-dependent activation of PI3Kγ 62, 63 . Further studies will be required to determine how this avenue might be used to control angiogenesis in both wound healing and metastasis. As shown in the top panel, a direct interaction between phosphodiesterase 3B (PDE3B) and exchange factor directly activated by cAMP (EPAC) promotes the formation of a plasma membrane signalosome that controls cAMP-mediated activation of RAS-related protein (RRAS) and its subsequent activation of the p84-regulatory domain-associated p110γ subunit of phosphoinositide 3-kinase γ and, ultimately, integrin-based adhesions with the extracellular matrix. A PDE3B-based, EPAC1-displacing peptide antagonizes PDE3B-EPAC1 protein-protein interactions (PPIs), allows localized increases in cAMP and promotes signalling through this signalosome 62 . As shown in the bottom panel, a direct interaction between PDE4D and EPAC1 promotes the integration of these proteins into a vascular endothelial cadherin-based signalosome that allows cAMP -acting through EPAC1-based activation of small GTPase RAS-related protein 1 (RAP1) -to regulate endothelial cell permeability. An EPAC1-based, PDE4D-displacing peptide antagonizes PDE4D-EPAC1 PPIs, interferes with the integration of these proteins into the signalosome and increases endothelial cell permeability 63 . HAEC, human arterial endothelial cell; PIP 3 , phosphatidylinositol-(3,4,5)-trisphosphate; PKB, protein kinase B. PDE8A. Recently, a crucial role was identified for the formation of a PDE8B-RAF1 complex in the control of PKA-dependent phosphorylation and inactivation of RAF1 in cells. Brown and co-workers 65 reported that a PDE8A-based RAF1-disrupting peptide promoted PKA-mediated phosphorylation of RAF1 in cells and thus provided mechanistic insights into the manner by which localized hydrolysis of cAMP has a crucial role in PKA-mediated phosphorylation and inhibition of RAF1. Given the importance of RAF1-mediated signalling in numerous systems, this mechanism may allow selective regulation of RAF1 activity in cells in which the actions of RAF1 are maladaptive, such as certain cancers.
Although we are only now beginning to identify where PDE-based signalosomes form and operate in cells, based on these examples it is likely that disrupting peptides, or small molecules with similar types of activities, will prove to be fruitful new therapeutic tools in the near future (TABLE 3) .
Allosteric modulators N-terminal regulatory domains in certain PDEs contain structural determinants that are essential for PDE oligomerization, and although some of these have been suggested to regulate the catalytic activity of PDEs, these regions have not yet been targeted in the development of PDE activators or inhibitors. For instance, PDE2, PDE5 and PDE6 family enzymes contain homologous N-terminal GAF domains (FIGS 1,5a) , which, upon cGMP binding, promote cyclic nucleotide hydrolysis via allosteric regulation of the distant C-terminal catalytic domain 3, 46 . Similarly, two N-terminal domains, termed upstream conserved region 1 (UCR1) and UCR2 (FIGS 1,5b,c) , form a functional module that regulates the catalytic activity of PDE4 as well as its oligomerization 3, 46, 163 . In this case, however, UCR-based regulation involves direct interactions between the UCR and the catalytic domain. A novel approach in the design of specific PDE inhibitors has focused on developing modulators that target and alter the interactions between N-terminal regulatory domains and their downstream catalytic domains.
GAF domain-based regulation. Crystallographic data of homodimeric PDE2A (FIG. 5a) showed that unliganded PDE2A GAF domains (GAFA and GAFB) are arranged to form a parallel dimer that hinders the access of substrates to both catalytic domains of the dimeric PDE2A complex 18, 164 . By contrast, the binding of cGMP to GAFB in PDE2A promoted the rotation of the monomeric catalytic domains, the removal of GAF-dependent steric hindrance and subsequent binding of the substrate 18, 164 (FIG. 5a) . Using this information, a chimaera was constructed in which the GAF domains of PDE5A were fused to the cGMP-and GAF-regulated cyanobacterial adenylyl cyclase (CyaB1), and this chimaera was used in a high-throughput screen to identify compounds that inhibited GAF-mediated activation of CyaB1 by cGMP, but not cGMP-independent cyclase activity 165 . At least two specific GAF inhibitors, which blocked cGMP-induced activation of CyaB1, but not the intrinsic catalytic function of the cyclase, were discovered and are being characterized 165 .
UCR-based regulation. Although the cAMP binding pockets of PDE4 subfamilies (PDE4A, PDE4B, PDE4C and PDE4D) exhibit subtle conformational differences 38 , the variation within these active sites is small. As a result, PDE4 subfamily selectivity cannot be achieved just by targeting the active site. Analyses of crystal structures of PDE4B or PDE4D in complex with certain inhibitors, such as RS25344, have indicated that a UCR2 fragment interacts with the inhibitor at the active site, allowing for direct regulation of catalytic activity by the UCR2 domain 35, 163 . Crystallographic studies have identified three distinct homodimeric conformations of PDE4 subfamily enzymes. In the 'open' conformation, each active site has direct access to cAMP and functions independently 38, 163 . As all PDE4 subfamily enzymes have a highly conserved active site, therapeutic agents that target this open conformer, including roflumilast, act as non-selective competitive inhibitors of all PDE4 enzymes (TABLE 2). In their 'closed' conformation, a C-terminal intramolecular helix 18, 164 . b | Ribbon diagram of the PDE4 catalytic domain (shown in pale cyan) with an upstream conserved region 2 (UCR2) fragment (shown in green). The PDE4-selective inhibitor RS25344 (shown in yellow) binds to the active site of PDE4 and also interacts with the UCR2 fragment. c | Detailed view of the interaction of RS25344 (shown in yellow) with PDE4D3 residues (shown in cyan and green; Protein Data Bank ID: 3G4G). Similar to other PDE4 inhibitors, the allosteric modulator RS25344 forms a conserved hydrogen bond with the invariant Gln535 and stacks against Phe538 in the catalytic pocket. However, RS25344 makes unique hydrophobic contacts with Phe196 and Val200 in the UCR2 helix, which 'caps' and interacts with the active site 35, 163 . in all PDE4 enzymes loops across the active site of each monomer to gate the access of cAMP to the catalytic site and to inhibit cAMP hydrolysis. In a third conformation, a UCR2-based helix from one monomer folds across and 'caps' the active site of the second monomer, and thus inhibits cAMP hydrolysis by the second monomer in 'trans' 15, 163 (FIG. 5b,c) . The equilibrium between the 'capped' and 'uncapped' states is influenced by extracellular signalregulated kinase (ERK)-induced phosphorylation and specific inhibitors.
Structures of PDE4B or PDE4D3 in complex with certain inhibitors, including RS25344, have shown that RS25344 binds to the active site but also forms contacts with a helical fragment in the UCR2 domain. These interactions between UCR2 and RS25344 increased the affinity of the inhibitor for the PDE4D3 active site 35, 47, 163 (FIG. 5b,c) .
UCR-mediated regulation of PDE4 activity is further regulated by the complex series of post-translational events and protein-protein interactions that PDEs are known to participate in 13, 92 . It should be noted, however, that although interactions between UCR2 and certain PDE4 inhibitors at the active site induce conformational changes that result in an increased affinity of the inhibitor at the active site, UCR-mediated regulation involves physical 'capping' and interactions at the active site and thus does not induce classical allostery. Classical allostery involves conformational changes and the transduction of intramolecular signals to the active site that arise through the interactions of ligands at regulatory sites that are distinct from the active site.
These multiple models have informed the development of PDE4D subtype-selective modulators that act as 'bidentate ligands' and bind simultaneously to both UCR2 and the active site to hold UCR2 in the closed position and partially inhibit PDE4 activity 35, 47, 163 . PDE4D subtype-selective inhibitors were designed by targeting a phenylalanine (in PDE4D) or tyrosine (in PDE4B) polymorphism in the UCR2 domain. One such PDE4D-selective allosteric regulator, D159687, was demonstrated to have potent anti-inflammatory effects in cell models and animal models, with minimal emesis, which suggests that it could have utility in inflammatory conditions such as COPD, asthma, psoriasis and arthritis 35, 163 . In addition, studies in mice suggest that compounds like D159687 may have applications in improving cognitive function and memory, as well as in the treatment of depression. Based on this work, similar allosteric modulators acting at the UCR2 domain of PDE4B and the catalytic site of PDE4B might provide effective suppression of inflammation in asthma 35, 47, 163 . As sequences of the N-terminal regulatory domains vary considerably across PDE families and subfamilies, it is anticipated that, given these early successes with allosteric modulators of PDE4, similar approaches aimed at antagonizing or promoting direct interactions between regulatory domains and catalytic sites in other PDEs will soon be underway.
Concluding remarks
Why are there so many PDEs? This question has been posed since the 1970s, well before the advent of molecular genetics. Based on the findings reviewed in this article, the signalosome concept has, in many respects, helped to provide the answer. Indeed, we suggest that the information reviewed herein is consistent with the notion that the tethering or targeting of individual PDEs to selected signalosomes at different subcellular locations allows individual PDEs to assume specific functional roles in the compartmentalized regulation of specific cyclic nucleotide signalling pathways, as well as physiological and pathophysiological responses. Moreover, as discussed above, we believe that by targeting individual signalosomes it will be possible to develop novel strategies to treat many diseases.
In addition, an increased understanding of the complexities of PDE biology, especially from the use of knockout and knockdown models of specific PDEs, has identified new targets for old and new drugs. These include PDE5 inhibitors for cardiovascular and metabolic diseases, PDE1C and PDE3A inhibitors for vascular remodelling, PDE1 and PDE10A inhibitors for schizophrenia, PDE7 inhibitors for inflammation, PDE4 inhibitors for diabetes, as well as PDE inhibitors in combination with other therapeutic modalities. This increased knowledge has also provided a conceptual framework for using multiple PDE inhibitors, inhibitors with mixed selectivities or non-selective inhibitors for complex diseases (TABLES 1,2,4).
As described above, the design of novel selective inhibitors is being increasingly driven by this improved understanding of the biology of PDEs and PDE inhibitors, as well as by structural insights from modern proteomics and X-ray crystallography of PDE catalytic cores and PDE-inhibitor co-crystal complexes, in addition to more complex structures. These studies have yielded information about the unique allosteric interactions between the regulatory and catalytic domains of PDEs, as well as between individual PDEs and their specific interacting partners (FIGS 4,5; TABLES 2-4). The design and delivery of novel selective agents, especially allosteric modulators (for example, PDE4D-selective inhibitors) and signalosome disruptors, will be challenging, but offers huge opportunities for the development of more specific and effective therapeutics.
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